Straits Times Index
3,292.93 -3.96 (-0.12%) Nikkei
38,236.07 -37.98 (-0.10%) Hang Seng
18,475.92 +268.79 (+1.48%) FTSE 100
8,213.49 +41.34 (+0.51%) Bitcoin USD
63,655.49 +2,059.38 (+3.34%) CMC Crypto 200
1,359.39 +82.41 (+6.45%)
Cidara Therapeutics, Inc. (CDTX)
After hours:
| Previous close | 12.68 |
| Open | 11.77 |
| Bid | 12.33 x 100 |
| Ask | 12.85 x 100 |
| Day's range | 11.75 - 13.20 |
| 52-week range | 10.00 - 29.60 |
| Volume | |
| Avg. volume | 60,692 |
| Market cap | 57.067M |
| Beta (5Y monthly) | 1.01 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GuruFocus.com
Steven Cohen's Point72 Adds Cidara Therapeutics to Its Portfolio
Steven Cohen (Trades, Portfolio)'s investment firm, Point72, has recently expanded its portfolio with the addition of Cidara Therapeutics Inc (NASDAQ:CDTX). On December 31, 2023, Point72 acquired 1,250,228 shares of the biotechnology company, reflecting a new position in the firm's diverse investment landscape. The transaction was executed at a trade price of $0.794 per share, marking a strategic move by one of the industry's leading investment entities.
- Zacks
Cidara (CDTX) Up on EC Nod for Rezzayo in Invasive Candidiasis
Cidara's (CDTX) Rezzayo (rezafungin acetate) gets approval from the European Commission for the treatment of invasive candidiasis in adults. The stock rises 11.1%.
- Zacks
Cidara Therapeutics (CDTX) Reports Q2 Loss, Lags Revenue Estimates
Cidara Therapeutics (CDTX) delivered earnings and revenue surprises of -75% and 46.90%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
